People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Consumer / Retail, Other, Biotechnology, Other Health Care, Manufacturing, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genius Brands International, Inc. | — | Consumer / Retail | Series C | $146.8M | $35.1M | 2019 |
| LJ/HAH Holdings Corp | — | Other | Series D+ | $117.7M | $2.0B | 2010 |
| Genomenon, Inc. | — | Biotechnology | Series B | $28.8M | $41.8M | 2020 |
| Icad Inc | — | Other Health Care | Series A | $27.1M | $302.7M | 2010 |
| Keystone Automotive Holdings, Inc. | — | Manufacturing | Series B | $15.9M | $174.3M | 2011 |
| Avenda Health, Inc. | — | Healthtech | Series A | $15.3M | $26.0M | 2019 |
| Xoft Inc | — | Other Health Care | Series A | $12.1M | $16.2M | 2009 |
| HOF Village, LLC | — | Other | Series A | $7.8M | $117.3M | 2018 |
| Walkthrough, Inc. | — | Other Technology | Seed | $1.8M | $51.1M | 2018 |
Michael Klein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Klein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mary Ann Sigler | 1 | 12 |
| Sean Ammirati | 1 | 11 |
| Michael Kaplan | 1 | 11 |
| Michael Gross | 1 | 9 |
| John Friedman | 1 | 9 |
| David Baker | 1 | 8 |
| David Singer | 1 | 7 |
| Jeffrey Bird | 1 | 5 |
| Eva M. Kalawski | 1 | 5 |
| Charles Moret | 1 | 4 |
| Arda Minocherhomjee | 1 | 4 |
| STEPHEN T. ZOLLO | 1 | 3 |
| Darlene Deptula-Hicks | 1 | 3 |
| JEFFREY BARNES | 1 | 3 |
| Paul Farmer | 1 | 3 |
| Patricia Glaza | 1 | 3 |
| Lawrence Howard | 1 | 3 |
| Terry Theodore | 1 | 3 |
| Rachel Brem | 1 | 2 |
| Klaus Moeller | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.